Ignite Creation Date:
2024-05-06 @ 4:06 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02453282
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-18
First Post:
2015-05-20
Brief Title:
Phase III Open Label First Line Therapy Study of MEDI 4736 Durvalumab With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer NSCLC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Organization Data
Organization:
AstraZeneca
Class:
INDUSTRY
Study ID:
D419AC00001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AstraZeneca
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None